The clinical application of UGT1A1 pharmacogenetic testing: Gene– environment interactions

Human Genomics

Volumn 4, Issue 4, 2010, Pages 238-249

  Marques, Sara Correia ^a,b   Ikediobi, Ogechi N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

Drug therapy; Ethnicity; Pharmacogenetics; Polymorphism; UDP glucuronosyltransferase; UGT1A1

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; GLUCURONOSYLTRANSFERASE; PHENOL GLUCURONOSYLTRANSFERASE;

DRUG ANTAGONISM; ENVIRONMENT; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; GENOTYPE; HUMAN; METHODOLOGY; PHARMACOGENETICS; POPULATION GENETICS; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ENVIRONMENT; ENZYME INHIBITORS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETICS, POPULATION; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

MLCS; MLOWN;

EID: 85027955716     PISSN: 14739542     EISSN: 14797364     Source Type: Journal    
DOI: 10.1186/1479-7364-4-4-238     Document Type: Review

References (50)

1. Strassburg, C.P. (2008), ‘Pharmacogenetics of Gilbert’s syndrome’, Pharmacogenomics Vol. 9, pp. 703–715.
2. Perera, M.A., Innocenti, F. and Ratain, M.J. (2008), ‘Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorph-isms: Are we there yet?’, Pharmacotherapy Vol. 28, pp. 755–768.
3. Kiang, T.K., Ensom, M.H. and Chang, T.K. (2005), ‘UDP-glucuronosyl-transferases and clinical drug-drug interactions’, Pharmacol. Ther. Vol. 106, pp. 97–132.
4. Lankisch, T.O., Behrens, G., Ehmer, U., Möbius, U. et al. (2009), ‘Gilbert’s syndrome and hyperbilirubinemia in protease inhibitor therapy — An extended haplotype of genetic variants increases risk in indinavir treatment’, J. Hepatol. Vol. 50, pp. 1010–1018.
5. Zhang, D., Zhang, D., Cui, D., Gambardella, J. et al. (2007), ‘Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism’, Drug Metab. Dispos. Vol. 35, pp. 2270–2280.
6. Innocenti, F., Iyer, L. and Ratain, M.J. (2001), ‘Pharmacogenetics of anticancer agents: Lessons from amonafide and irinotecan’, Drug Metab. Dispos. Vol. 29, pp. 596–600.
7. Duguay, Y., McGrath, M., Lépine, J., Gagné, J.F. et al. (2004), ‘The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk’, Cancer Res. Vol. 64, pp. 1202–1207.
8. Guillemette, C., Millikan, R.C., Newman, B., Housman, D.E. et al. (2000), ‘Genetic polymorphisms in uridine diphospho-glucuronosyltrans-ferase 1A1 and association with breast cancer among African Americans’, Cancer Res. Vol. 60, pp. 950–956.
9. Sparks, R., Ulrich, C.M., Bigler, J., Tworoger, S.S. et al. (2004), ‘UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients’, Breast Cancer Res. Vol. 6, pp. R488–R498.
10. Jemnitz, K., Lengyel, G. and Vereczkey, L. (2002), ‘In vitro induction of bilirubin conjugation in primary rat hepatocyte culture’, Biochem. Biophys. Res. Commun. Vol. 291, pp. 29–33.
11. Wenning,L.A.,Hanley,W.D.,Brainard,D.M.,Petry,A.S.et al. (2009), ‘Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharma-cokinetics of raltegravir’, Antimicrob. Agents Chemother. Vol. 53, pp. 2852–2856.
12. Brierley, C.H., Senafi, S.B., Clarke, D., Hsu, M.H. et al. (1996), ‘Regulation of the human bilirubin UDP-glucuronosyltransferase gene’, Adv. Enzyme Regul. Vol. 36, pp. 85–97.
13. Ramírez, J., Komoroski, B.J., Mirkov, S., Graber, A.Y. et al. (2006), ‘Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes’, Pharmacogenet. Genomics Vol. 16, pp. 79–86.
14. Innocenti, F., Undevia, S.D., Iyer, L., Chen, P.X. et al. (2004), ‘Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan’, J. Clin. Oncol. Vol. 22, pp. 1382–1388.
15. Hoskins, J.M., Goldberg, R.M., Qu, P., Ibrahim, J.G. et al. (2007), ‘UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters’, J. Natl. Cancer Inst. Vol. 99, pp. 1290–1295.
16. Cecchin, E., Innocenti, F., D’Andrea, M., Corona, G. et al. (2009), ‘Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan’, J. Clin. Oncol. Vol. 27, pp. 2457–2465.
17. Corona, G., Vaccher, E., Sandron, S. et al. (2008), ‘Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi’s sarcoma’, Clin. Pharm. Ther. Vol. 83, pp. 601–606.
18. Trontelj, J., Marc, J., Zavratnik, A., Bogataj, M. et al. (2009), ‘Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and phar-macodynamics’, Br. J. Clin. Pharmacol. Vol. 67, pp. 437–444.
19. Wenning, L.A., Petry, A.S., Kost, J.T., Jin, B. et al. (2009), ‘Pharmacokinetics of raltegravir in individuals with UGT1A1 poly-morphisms’, Clin. Pharmacol. Ther. Vol. 85, pp. 623–627.
20. Placeres Alsina, M.M., Tuset Creus, M. and Miró, J.M. (2008), ‘Pharmacokinetics and interactions of raltegravir’, Enferm. Infecc. Microbiol. Clin. Vol. 26, pp. 23–28.
21. Rotger, M., Taffé, P., Bleiber, G., Gunthard, H.F. et al. (2005), ‘Gilbert syndrome and the development of antiretroviral therapy-associated hyper-bilirubinemia’, J. Infect. Dis. Vol. 192, pp. 1381–1386.
22. Lankisch, T.O., Moebius, U., Wehmeier, M., Behrens, G. et al. (2006), ‘Gilbert’s disease and atazanavir: From phenotype to UDP-glucuronosyl-transferase haplotype’, Hepatology Vol. 44, pp. 1324–1332.
23. Anderson, P.L., Aquilante, C.L., Gardner, E.M., Predhomme, J. et al. (2009), ‘Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors’, J. Antimicrob. Chemother. Vol. 64, pp. 1071–1079.
24. Anderson, P.L., Lamba, J., Aquilante, C.L., Schuetz, E. et al. (2006), ‘Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: A pilot study’, J. Acquir. Immune Defic. Syndr. Vol. 42, pp. 441–449.
25. Meza-Junco, J., Chu, Q.S., Christensen, O., Rajagopalan, P. et al. (2009), ‘UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib’, Cancer Chemother. Pharmacol. Vol. 65, pp. 1–4.
26. Mross, K., Steinbild, S., Baas, F., Gmehling, D. et al. (2007), ‘Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib’, Eur. J. Cancer Vol. 43, pp. 55–63.
27. Wen,Z.,Tallman,M.N.,Ali,S.Y.andSmith,P.C.(2007),‘UDP-glucuro-nosyltransferase 1A1 is the principal enzyme responsible for etoposide glu-curonidation in human liver and intestinal microsomes: Structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics’, Drug Metab. Dispos. Vol. 35, pp. 371–380.
28. Biondi, M.L., Turri, O., Dilillo, D., Stival, G. et al. (1999), ‘Contribution of the TATA-box genotype (Gilbert syndrome) to serum bilirubin concentrations in the Italian population’, Clin. Chem. Vol. 45, pp. 897–898.
29. Te Morsche, R.H., Zusterzeel, P.L., Raijmakers, M.T., Roes, E.M. et al. (2001), ‘Polymorphism in the promoter region of the bilirubin UDP-glucuronosyltransferase (Gilbert’s syndrome) in healthy Dutch sub-jects’, Hepatology Vol. 33, p. 765.
30. Fernández Salazar, J.M., Remacha Sevilla, A., del Río Conde, E. and Baiget Bastús, M. (2000), ‘Distribution of the A(TA)7TAA genotype associated with Gilbert syndrome in the Spanish population’, Med. Clin. (Barc.) Vol. 115, pp. 540–541.
31. Burchell, B. and Hume, R. (1999), ‘Molecular genetic basis of Gilbert’s syndrome’, J. Gastroenterol. Hepatol. Vol. 14, pp. 960–966.
32. Fertrin, K.Y., Gonçalves, M.A., Saad, S.T. and Costa, F.F. (2002), ‘Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil’, Am. J. Med. Genet. Vol. 118, pp. 117–119.
33. Premawardhena, A., Fisher, C.A., Liu, Y.T., Verma, I.C. et al. (2003), ‘The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): Hematologic and evolutionary implications’, Blood Cells Mol. Dis. Vol. 31, pp. 98–101.
34. Jada, S.R., Lim, R., Wong, C.I., Shu, X. et al. (2007), ‘Pole of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C.A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients’, Cancer Sci. Vol. 98, pp. 1461–1467.
35. Zhang, A., Xing, Q., Qin, S., Du, J. et al. (2007), ‘Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations’, Pharmacogenomics J. Vol. 7, pp. 333–338.
36. Boyd, M.A., Srasuebkul, P., Ruxrungtham, K., Mackenzie, P.I. et al. (2006), ‘Relationship between hyperbilirubinaemia and UDP-glucuronosyltransfer-ase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir’, Pharmacogenet. Genomics Vol. 16, pp. 321–329.
37. Takeuchi, K., Kobayashi, Y., Tamaki, S. et al. (2004), ‘Genetic polymorphisms of bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert’s syndrome as well as in healthy Japanese subjects’, J. Gastroenterol. Hepatol. Vol. 19, pp. 1023–1028.
38. Sekine, I., Yamamoto, N., Nishio, K. and Saijo, N. (2008), ‘Emerging ethnic differences in lung cancer therapy’, Br.J.CancerVol. 99, pp. 1757–1762.
39. Beutler, E., Gelbart, T. and Demina, A. (1998), ‘Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced poly-morphism for regulation of bilirubin metabolism?’, Proc. Natl. Acad. Sci. USAVol. 95, pp. 8170–8174.
40. Brites, D., Fernandes, A., Falcão, A.S., Gordo, A.C. et al. (2009), ‘Biological risks for neurological abnormalities associated with hyperbilir-ubinemia’, J. Perinatol. Vol. 29 (Suppl. 1), pp. S8–13.
41. van der Bol, J.M., Mathijssen, R.H., Loos, W.J., Friberg, L.E. et al. (2007), ‘Cigarette smoking and irinotecan treatment: Pharmacokinetic interaction and effects on neutropenia’, J. Clin. Oncol. Vol. 25, pp. 2719–2726.
42. Peterson, S., Bigler, J., Horner, N.K., Potter, J.D. et al. (2005), ‘Cruciferae interact with the UGT1A1*28 polymorphism to determine serum biliru-bin levels in humans’, J. Nutr. Vol. 135, pp. 1051–1055.
43. Court, M.H. (2010), ‘Interindividual variability in hepatic drug glucuro-nidation: Studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system’, Drug Metab. Rev. Vol. 42, pp. 202–217.
44. Saracino, M.R., Bigler, J., Schwarz, Y., Chang, J.L. et al. (2009), ‘Citrus fruit intake is associated with lower serum bilirubin concentration among women with the UGT1A1*28 polymorphism’, J. Nutr. Vol. 139, pp. 555–560.
45. Chang, J.L., Bigler, J., Schwarz, Y., Li, S.S. et al. (2007), ‘UGT1A1 poly-morphism is associated with serum bilirubin concentrations in a random-ized, controlled, fruit and vegetable feeding trial’, J. Nutr. Vol. 137, pp. 890–897.
46. Cheng, T.O. (2007), ‘Green tea may inhibit warfarin’, Int. J. Cardiol. Vol. 115, p. 236.
47. Cheng, T.O. (2008), ‘Not only green tea but also green leafy vegetables inhibit warfarin’, Int. J. Cardiol. Vol. 125, p. 101.
48. Ikediobi, O.N., Shin, J., Nussbaum, R.L., Phillips, K.A. et al. (2009), ‘Addressing the challenges of the clinical application of pharmacogenetic testing’, Clin. Pharmacol. Ther. Vol. 86, pp. 28–31.
49. Gold, H.T., Hall, M.J., Blinder, V. and Schackman, B.R. (2009), ‘Cost-effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for meta-static colorectal cancer’, Cancer Vol. 115, pp. 3858–3867.
50. Obradovic, M., Mrhar, A. and Kos, M. (2008), ‘Cost-effectiveness of UGT1A1 genotyping in second line, high-dose, once every 3 weeks irinotecan mono-therapy treatment of colorectal cancer. Pharmacogenomics Vol. 9, pp. 539–549.